Invest in the Future of Microbiome Innovation
Join Branchpoint Biosciences in Transforming Healthcare
Branchpoint Biosciences is dedicated to revolutionizing microbiome research and diagnostics through innovative qPCR-based technologies that deliver unparalleled accuracy and insights.
We are advancing the understanding of the microbiome’s impact on human health through our innovative qMA assays and qMP platforms. By delivering highly accurate and cost-effective data, we empower the development of new treatments, Live Biotherapeutic Products, and diagnostics. Our strategy focuses on creating multiple sustainable revenue streams and building strong support within the scientific community by introducing groundbreaking product modalities.
The North American microbiome market is projected to reach $1.8 billion by 2027, driven by increased recognition of the microbiome’s role in human health with 18% CAGR.
Industry Challenges
The microbiome research and diagnostics field is hindered by high costs, limited accuracy, and complex data analysis associated with traditional technologies like next-generation sequencing (NGS). These challenges make it difficult for researchers and organizations to conduct large-scale studies, develop new treatments, and bring innovative diagnostics to market efficiently.
Our Solution
Branchpoint Biosciences overcomes these obstacles with our innovative qPCR-based technologies - qMA™ assays and qMP™ platforms. We provide highly accurate and cost-effective microbiome profiling that simplifies data analysis and reduces reliance on expensive equipment and specialized expertise. By enabling precise, rapid, and scalable solutions, we can accelerate discoveries, validate bacterial biomarkers, and develop new treatments and diagnostics more effectively.
Co-founders Dr. Benjamin Tully, CEO & Dr. Christopher Corzett, CSO: With over 15 years of experience in microbiome research, Drs. Tully and Corzett lead Branchpoint Biosciences with a vision to transform healthcare through innovative diagnostics.
Join us in advancing microbiome research and transforming healthcare. Contact us to learn more about investment opportunities with Branchpoint Biosciences.
Disclaimer: This page contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected.